414 related articles for article (PubMed ID: 25271436)
1. Development of nanoscale approaches for ovarian cancer therapeutics and diagnostics.
Engelberth SA; Hempel N; Bergkvist M
Crit Rev Oncog; 2014; 19(3-4):281-315. PubMed ID: 25271436
[TBL] [Abstract][Full Text] [Related]
2. Nanotechnological approaches for diagnosis and treatment of ovarian cancer: a review of recent trends.
Ding H; Zhang J; Zhang F; Xu Y; Liang W; Yu Y
Drug Deliv; 2022 Dec; 29(1):3218-3232. PubMed ID: 36259505
[TBL] [Abstract][Full Text] [Related]
3. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer.
Rose PG
Oncologist; 2005 Mar; 10(3):205-14. PubMed ID: 15793224
[TBL] [Abstract][Full Text] [Related]
4. A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles.
Waterhouse DN; Tardi PG; Mayer LD; Bally MB
Drug Saf; 2001; 24(12):903-20. PubMed ID: 11735647
[TBL] [Abstract][Full Text] [Related]
5. Potential nanotechnologies and molecular targets in the quest for efficient chemotherapy in ovarian cancer.
Rhoda K; Choonara YE; Kumar P; Bijukumar D; du Toit LC; Pillay V
Expert Opin Drug Deliv; 2015 Apr; 12(4):613-34. PubMed ID: 25300775
[TBL] [Abstract][Full Text] [Related]
6. Nanotechnology in ovarian cancer: Diagnosis and treatment.
Barani M; Bilal M; Sabir F; Rahdar A; Kyzas GZ
Life Sci; 2021 Feb; 266():118914. PubMed ID: 33340527
[TBL] [Abstract][Full Text] [Related]
7. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy.
Gabizon AA
Cancer Invest; 2001; 19(4):424-36. PubMed ID: 11405181
[TBL] [Abstract][Full Text] [Related]
8. Nanotechnology and Immunotherapy in Ovarian Cancer: Tracing New Landscapes.
Corradetti B; Pisano S; Conlan RS; Ferrari M
J Pharmacol Exp Ther; 2019 Sep; 370(3):636-646. PubMed ID: 30737357
[TBL] [Abstract][Full Text] [Related]
9. Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma.
Duggan ST; Keating GM
Drugs; 2011 Dec; 71(18):2531-58. PubMed ID: 22141391
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and toxicity profile of pegylated liposomal doxorubicin in patients with advanced ovarian cancer.
Mayer C; Brucker J; Schuetz F; Domschke C; Bechstein S; Heil J; Golatta M; Wallwiener M; Sohn C; Schneeweiss A; Rom J
Arch Gynecol Obstet; 2016 Jul; 294(1):123-9. PubMed ID: 26498757
[TBL] [Abstract][Full Text] [Related]
11. Nanoformulations for therapy of pancreatic and liver cancers.
de Souza PC; Ranjan A; Towner RA
Nanomedicine (Lond); 2015 May; 10(9):1515-34. PubMed ID: 25996122
[TBL] [Abstract][Full Text] [Related]
12. Role of pegylated liposomal doxorubicin (PLD) in epithelial ovarian cancer.
Lorusso D; Ferrandina G; Lo Voi R; Fagotti A; Scambia G
J Chemother; 2004 Nov; 16 Suppl 4():98-103. PubMed ID: 15688622
[TBL] [Abstract][Full Text] [Related]
13. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
14. New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy.
Gabizon AA; Patil Y; La-Beck NM
Drug Resist Updat; 2016 Nov; 29():90-106. PubMed ID: 27912846
[TBL] [Abstract][Full Text] [Related]
15. A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer.
Adams SF; Marsh EB; Elmasri W; Halberstadt S; Vandecker S; Sammel MD; Bradbury AR; Daly M; Karlan B; Rubin SC
Gynecol Oncol; 2011 Dec; 123(3):486-91. PubMed ID: 21945552
[TBL] [Abstract][Full Text] [Related]
16. Topotecan and doxorubicin combination to treat recurrent ovarian cancer: the influence of drug exposure time and delivery systems to achieve optimum therapeutic activity.
Patankar NA; Pritchard J; van Grinsven M; Osooly M; Bally MB
Clin Cancer Res; 2013 Feb; 19(4):865-77. PubMed ID: 23303216
[TBL] [Abstract][Full Text] [Related]
17. Novel nanotechnology approaches to diagnosis and therapy of ovarian cancer.
Kim PS; Djazayeri S; Zeineldin R
Gynecol Oncol; 2011 Mar; 120(3):393-403. PubMed ID: 21168905
[TBL] [Abstract][Full Text] [Related]
18. Is it equivalent? Evaluation of the clinical activity of single agent Lipodox® compared to single agent Doxil® in ovarian cancer treatment.
Smith JA; Costales AB; Jaffari M; Urbauer DL; Frumovitz M; Kutac CK; Tran H; Coleman RL
J Oncol Pharm Pract; 2016 Aug; 22(4):599-604. PubMed ID: 26183293
[TBL] [Abstract][Full Text] [Related]
19. New trends in diagnosing and treating ovarian cancer using nanotechnology.
Zhang J; Ding H; Zhang F; Xu Y; Liang W; Huang L
Front Bioeng Biotechnol; 2023; 11():1160985. PubMed ID: 37082219
[TBL] [Abstract][Full Text] [Related]
20. Caelyx/Doxil for the treatment of metastatic ovarian and breast cancer.
Tejada-Berges T; Granai CO; Gordinier M; Gajewski W
Expert Rev Anticancer Ther; 2002 Apr; 2(2):143-50. PubMed ID: 12113236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
